Slice of Healthcare

The episode has a few genuinely informative moments - the GLP1/SSRI drug interaction patient case and the dialysis-diabetes gap - but these are surrounded by extended marketing language, repetitive fragmentation narratives, and high-level platitudes that dilute the useful content-per-minute ratio.

“this particular patient also had major depressive disorder and had been prescribed an ssri, which it is, has uh, an appetite suppression side effect to it that medication does”

“half of people who are on dialysis are diabetics. And many of those people do not have endocrine endocrinologists”

Almost every major argument - fragmentation is bad, point solutions fail, AI should augment not replace clinicians, need longitudinal coordination - is a standard industry refrain with no contrarian angle, first-principles reasoning, or genuinely fresh framing.

“Managing chronic and cardiometabolic disease through integrated coordinated care instead of reactive, episodic and self driven interventions”

“Where we have gone wrong is we haven't coordinated things together well, and brought the clinicians along with that”

Both guests are legitimate operators with relevant domain depth - the CEO built a multi-state medical practice and the CCO has 20+ years in the space - but neither is a recognisable at-scale executive and the interview leans heavily toward company promotion rather than hard-won practitioner knowledge.

“I joined this company in January of 2020, 2021. At the time we were running a clinical study to prove that diabetes management could be performed virtually”

“we're working with um, some chronic conditioned, uh, chronic kidney disease patients that are on dialysis and we're actually supporting them”

The GLP1 drug pipeline section is unusually granular - naming Fonbio, Retatrutide, Cagrosema, Maritide, Viking Therapeutics, Zealand, muscle-sparing combination therapies - and the $50B federal funding figure and dialysis statistic add real texture, lifting this dimension noticeably above average.

“We have the FDA's approved what's called Fonbio now that's Lilly's pill form of a drug. We have a wegovy pill, of course we have the high, high dose version of WeGovy WeGovy, there's Cagrosema. We just saw a readout from Lilly about for next year as is probably the most highly anticipated approval. Reddit Trutide, they're triple agonist”

“$50 billion in federal funding to transform rural health and chronic condition management”

The host poses broad, open-ended setup questions and never follows up with a specific challenge, number request, or pushback on any claim; the result is an extended company pitch with no productive friction or moment of genuine interrogation.

“without calling out anyone in particular, what did some of these other platforms out there, tools, apps, what do they get wrong?”

“If Cecilia Health works exactly the way you want it to over the next five years, what changes?”